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Abstract
Background: Limited data are available comparing the combined effects of statins and renin–an-
giotensin system inhibitor (RASI) between patients with ST-segment elevation myocardial infarction 
(STEMI) and those with non-STEMI (NSTEMI). We compared the effects of statins combined with 
RASI in STEMI and NSTEMI patients after stent implantation during a 2-year follow-up period.
Methods: A total of 21,890 acute myocardial infarction (AMI) patients who underwent successful 
stent implantation and who received statins with RASI were enrolled. They were separated into the 
STEMI group (n = 12,490) and the NSTEMI group (n = 9400). The major clinical endpoint was the 
occurrence of major adverse cardiac events (MACEs) defined as all-cause death, recurrent myocardial 
infarction (Re-MI), and any repeat revascularization.
Results: Two propensity score-matched groups (5891 pairs, n = 11,782, C-statistic = 0.821) were 
generated. Even though the cumulative incidences of MACE, Re-MI, total repeat revascularization 
were similar between the two groups, the cumulative incidences of all-cause death (hazard ratio [HR] 
1.407; 95% confidence interval [CI] 1.106–1.790; p = 0.005) and cardiac death (HR 1.311; 95% CI 
0.983–1.749; p = 0.046) were significantly higher in the NSTEMI group. 
Conclusions: In this study, statin with RASI combination therapy was more beneficial to the STEMI 
patients than to the NSTEMI patients in reducing all-cause death and cardiac death. (Cardiol J)
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Intensive statin therapy has produced greater 
reductions in the risks of cardiovascular death, non-
-fatal myocardial infarction (MI), ischemic stroke, 
and coronary revascularization than less intensive 
statin therapy in patients with acute coronary syn-
drome [1–3]. Moreover, stains are recommended 
for all acute MI (AMI) patients, regardless of cho-
lesterol concentration at presentation [4–6]. More 
recently, Kim et al. [7] reported that statin therapy 
was more effective in reducing the cumulative 
risks of major adverse cardiac events (MACEs), 
all-cause death, and target vessel revasculariza-
tion (TVR) in a ST-segment elevation myocardial 
infarction (STEMI) group than in a non-STEMI 
(NSTEMI) group in Korean patients with AMI after 
successful drug-eluting stent (DES) implantation. 
Current guidelines recommended that angiotensin-
-converting enzyme inhibitors (ACEIs) should be 
prescribed within the first 24 hours for all AMI 
patients with left ventricular (LV) systolic dys-
function, unless contraindicated. Furthermore, the 
patients who do not tolerate ACEIs should be given 
angiotensin receptor blockers (ARBs) [5, 6, 8, 9]. 
A previous report [10] showed that the mortality 
reduction capability of renin–angiotensin system 
inhibitors (RASIs) was more prominent in STEMI 
patients compared with NSTEMI patients. Hence, 
combination therapy with statins and RASIs may be 
an important treatment modality in patients with 
hypertension, hypercholesterolemia, diabetes, 
metabolic syndrome, or obesity, to reduce or pre-
vent cardiovascular disease [11, 12]. Nevertheless, 
the data concerning long-term clinical outcomes of 
statin with RASI combination therapy in patients 
with STEMI and NSTEMI after stent implantation 
are limited. Therefore, we compared the effects of 
statins combined with RASI in STEMI and NSTEMI 
patients after successful percutaneous coronary 
intervention (PCI) over a 2-year follow-up period.
Methods
Study design and population
The study population of this non-randomized, 
multicenter, observational, retrospective cohort 
study was obtained from the Korea AMI Regis-
try (KAMIR). KAMIR was designed to capture 
real-world treatment practices and the short- and 
long-term outcomes of AMI patients; to evalu-
ate the current epidemiology and analyze the 
prognostic factors of AMI; and to improve the 
long-term prognosis of the individual patients. 
Eligible patients were ≥ 18 years of age at the 
time of hospital admission [13]. A total of 45,863 
AMI patients who underwent successful stent im-
plantation from November 2005 to June 2015 were 
evaluated. This study protocol was approved by the 
ethics committee at each participating center, and 
informed consent was obtained from all individual 
participants prior to enrollment. These processes 
were conducted according to the ethical guidelines 
of the 1975 Declaration of Helsinki. The exclusion 
criteria were as follows: (1) incomplete laboratory 
results (n = 10,506, 22.9%); (2) lost to follow-up 
(n = 2562, 5.6%); (3) statin and RASI had not 
been prescribed (n = 2392, 5.2%); (4) statin only 
prescribed (n = 4409, 9.6%); and (5) RASI only pre-
scribed (n = 4185, 9.1%). Finally, a total of 21,890 
AMI patients who underwent successful stent 
implantation and who had been prescribed both sta-
tin and RASI were enrolled. Among these, 12,490 
(57.1%) were STEMI patients and the remaining 
9400 (42.9%) were NSTEMI patients (Fig. 1). 
Any information concerning adverse events in 
these 21,890 participants with AMI including the 
time intervals and the types of events after the 
index PCI, which occurred during the follow-up 
period, was monitored at the outpatient clinic, by 
phone calls, or by reviewing the patients’ charts 
at each participating center, and all participants 
completed a 2-year clinical follow-up [14]. 
PCI procedure and medical treatment
Diagnostic coronary angiography and PCI were 
performed after an administration of unfractionated 
heparin (50–100 IU/kg) according to standard tech-
nique [15]. Before PCI, all patients received loading 
doses of acetylsalicylic acid (ASA) 200–300 mg and 
clopidogrel 300–600 mg; alternatively, ticagrelor 
180 mg or prasugrel 60 mg was administered. 
Moreover, dual antiplatelet therapy (DAPT), such 
as a daily dose of 100 mg ASA and 75 mg clopi-
dogrel or ticagrelor 90 mg twice daily or prasugrel 
5–10 mg/day, was recommended for more than 
12 months after PCI. The choice of triple antiplatelet 
therapy (cilostazol 100 mg twice daily added to 
DAPT) was determined by the discretion of the in-
dividual operators [10]. The statins and their doses 
were as follows: 10–40 mg of atorvastatin, 5–10 mg 
of rosuvastatin, 2–4 mg of pitavastatin, 10–40 mg 
of simvastatin, 10–40 mg of pravastatin, 80 mg 
fluvastatin, and 50–100 mg lovastatin per day. 
The RASI used and their doses were as follows: 12.5–
–75 mg of captopril, 2.5–10 mg of ramipril, 2–8 mg 
of perindopril, 1.25–5 mg of cilazapril, 5–10 mg of 
imidapril, 7.5–15 mg of moexipril, 2.5–10 mg of 
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enalapril, 5–10 mg of lisinopril, 10 mg of fosinopril, 
3.75–7.5 mg of zofenopril, 25–100 mg of losartan, 
150–300 mg of irbesartan, 40–160 mg of valsartan, 
40–80 mg of telmisartan, 10–20 mg of olmesartan, 
4–32 mg of candesartan, 600 mg of eprosartan, and 
30–120 mg of fimasartan per day.
Study definitions and clinical outcomes
According to the current guidelines [6, 8], 
STEMI was defined as follows: ongoing chest pain 
and admission electrocardiogram showing ST-
segment elevation in at least 2 contiguous leads 
of ≥ 2 mm (0.2 mV) in men or ≥ 1.5 mm (0.15 mV) 
in women in leads V2–V3 and/or of ≥ 1 mm 
(0.1 mV) in other contiguous chest leads or the limb 
leads; or new-onset left bundle branch block [8]. 
NSTEMI was defined as follows: absence of persis-
tent ST-segment elevation with increased cardiac 
biomarkers and appropriate clinical context [6]. 
In the present study, early invasive treatment 
strategy was defined as performing PCI within 
24 hours after admission [10]. The major clinical 
endpoint was the occurrence of MACEs, defined 
as all-cause death, recurrent myocardial infarction 
(Re-MI), and any coronary repeat revascularization 
during a 2-year follow-up period. Any coronary 
repeat revascularization comprised target lesion 
revascularization (TLR), TVR, and non-TVR. All-
cause death was classified as cardiac death (CD) 
or non-CD. Re-MI was defined as the presence of 
clinical symptoms, electrocardiographic changes, 
or abnormal imaging findings of MI combined with 
an increase in the creatine kinase myocardial band 
(CK-MB) fraction above the upper normal limits 
or an increase in troponin-T/troponin-I to greater 
than the 99th percentile of the upper normal limit 
after the index PCI [10]. The definitions of TLR, 
TVR, and non-TVR were previously published [10].
Statistical analyses
For continuous variables, differences between 
groups were evaluated with the unpaired t-test. 
Data are expressed as mean ± standard deviation. 
For discrete variables, differences are expressed 
as counts and percentages, and were analyzed with 
c2 test or Fisher’s exact test between the groups. 
Various clinical outcomes were estimated using the 
Kaplan-Meier method, and differences between the 
two groups were compared by the log-rank test. To 
adjust for potential confounders, propensity score-
matched (PSM) analysis was performed. We tested 
all available variables that could be of potential 
relevance: baseline clinical, laboratory, angio-
graphic, and procedural characteristics (Table 1). 
The C-statistic for PSM was 0.821. Subjects were 
matched with a caliper width equal to 0.01. The 
procedure yielded 5891 matched pairs except for 
the serum levels of CK-MB and troponin-I. Many 
patients were excluded during this PSM analysis; 
to overcome this limitation, we performed mul-
tivariate analysis. Any variable with a p value of 
< 0.001 in univariate analysis and conventional risk 
factors of a poor outcome in the AMI population 
were considered as potential confounding factors 
and entered into the multivariate analysis (Table 2). 
Using Kaplan-Meier analysis, the differences 
Exclusion
— Incomplete laboratory results (n = 10,506)
— Lost to follow-up (n = 2562)
— Statin and RASI had not been prescribed (n = 2392)
— Statin alone (n = 4409)
— RASI alone (n = 4185)
A total of 45,863 AMI patients who underwent successful stent implantaion in the KAMIR were eligible from Novmber 2005 to June 2015
Finally, a total of 21,890 AMI patients who underwent successful stent implantation and who had been prescribed both statin and RASI were enrolled
Propensity score-matched
STEMI (n = 12,490)
STEMI (n = 5891)
NSTEMI (n = 9400)
NSTEMI (n = 5891)
Figure 1. Flow chart; AMI — acute myocardial infarction; KAMIR — Korea Acute Myocardial Infarction Registry; 
NSTEMI — non-ST-segment elevation myocardial infarction; RASI — renin–angiotensin system inhibitor; STEMI — 
ST-segment elevation myocardial infarction.
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Table 1. Baseline clinical, laboratory, angiographic, and procedural characteristics.










Age [years] 61.9 ± 12.6 64.2 ± 12.0 < 0.001 63.3 ± 12.5 63.3 ± 12.2 0.654
Men 9638 (77.2%) 6622 (70.4%) < 0.001 4361 (74.0%) 4350 (73.8%) 0.817
LVEF [%] 51.5 ± 10.8 54.6 ± 11.1 < 0.001 53.5 ± 10.9 53.8 ± 11.0 0.136 
BMI [kg/m2] 24.2 ± 3.1 24.2 ±3.1 0.448 24.1 ± 3.0 24.2 ± 3.0 0.525
SBP [mmHg] 129.1 ± 27.8 135.1 ± 26.3 < 0.001 132.6 ± 26.8 132.8 ± 26.1 0.587 
DBP [mmHg] 79.2 ± 16.8 81.1 ± 15.3 < 0.001 80.2 ± 15.8 80.4 ± 15.5 0.624
Cardiogenic shock 645 (5.2%) 154 (1.6%) < 0.001 129 (2.2%) 137 (2.3%) 0.620
CPR on admission 358 (2.9%) 133 (1.4%) < 0.001 119 (2.0%) 105 (1.8%) 0.345
Hypertension 5831 (46.7%) 5117 (54.4%) < 0.001 3010 (51.1%) 3004 (51.0%) 0.912
Diabetes mellitus 2944 (23.6%) 2762 (29.4%) < 0.001 1568 (26.6%) 1582 (26.9%) 0.771
Dyslipidemia 1383 (11.1%) 1246 (13.3%) < 0.001 723 (12.3%) 692 (11.7%) 0.380
Previous MI 334 (2.7%) 458 (4.9%) < 0.001 226 (3.8%) 213 (3.6%) 0.527
Previous PCI 514 (4.1%) 701 (7.5%) < 0.001 332 (5.6%) 332 (5.6%) 1.000
Previous CABG 38 (0.3%) 63 (0.7%) < 0.001 27 (0.5%) 29 (0.5%) 0.789
Previous HF 71 (0.6%) 131 (1.4%) < 0.001 46 (0.8%) 41 (0.7%) 0.591 
Previous CVA 637 (5.1%) 670 (7.1%) < 0.001 353 (6.0%) 362 (6.1%) 0.728
Current smokers 6067 (48.6%) 3620 (38.5%) < 0.001 2549 (43.3%) 2546 (43.2%) 0.956 
CK-MB [mg/dL] 171.3 ± 216.0 65.3 ± 168.6 < 0.001 101.4 ± 214.8 82.0 ± 207.2 < 0.001
Troponin-I [ng/mL] 59.6 ± 126.9 23.1 ± 43.5 < 0.001 37.8 ± 155.3 28.6 ± 52.4 < 0.001
NT-proBNP [pg/mL] 1497.5 ± 2832.4 2101.7 ± 4751.4 < 0.001 1748.2 ± 3636.7 1761.3 ± 3162.3 0.836 
hs-CRP [mg/dL] 10.9 ± 51.0 11.9 ± 55.9 0.207 11.5 ± 52.0 11.1 ± 45.3 0.616
Serum creatinine [mg/L] 1.05 ± 1.00 1.09 ± 1.16 0.007 1.06 ± 1.00 1.07 ± 1.07 0.667 
Blood glucose [mg/dL] 170.8 ± 72.3 158.5 ± 76.2 < 0.001 162.4 ± 65.1 161.2 ± 79.5 0.348
Total cholesterol [mg/dL] 186.8 ± 43.4 185.0 ± 45.6  0.004 185.9 ± 43.6 185.7 ± 45.9 0.818
Triglyceride [mg/L] 136.4 ± 113.3 136.3 ± 108.3 0.943 136.4 ± 112.8 137.2 ± 113.6 0.702
HDL cholesterol [mg/L] 44.2 ± 19.3 43.5 ± 15.4 0.001 43.8 ± 19.4 43.6 ± 16.3 0.638
LDL cholesterol [mg/L] 119.0 ± 38.8 117.7 ± 39.4  0.016 117.9 ± 38.8 117.8 ± 39.9 0.874
Discharge medications:
ASA 12430 (99.5%) 9341 (99.4%) 0.142 5859 (99.5%) 5856 (99.4%) 0.713
Clopidogrel 11212 (89.8%) 8340 (88.7%)  0.013 5263 (89.3%) 5247 (89.1%) 0.635
Ticagrelor 727 (5.8%) 625 (6.6%)  0.012 366 (6.2%) 365 (6.2%) 0.970
Prasugrel 438 (3.5%) 344 (3.7%)  0.547 208 (3.5%) 223 (3.8%) 0.462
Cilostazol 3077 (24.6%) 2202 (23.4%)  0.038 1366 (23.2%) 1386 (23.5%) 0.663
Beta-blockers 10824 (86.7%) 8082 (86.0%)  0.145 5094 (86.5%) 5114 (86.8%) 0.588
CCB 549 (4.4%) 824 (8.8%) < 0.001 354 (6.0%) 350 (5.9%) 0.876
Angiographic and procedural characteristics
PCI within 24 hours 11668 (93.4) 7444 (79.2) < 0.001 5203 (88.3) 5213 (88.5) 0.774
Infarct-related artery:
Left main 112 (0.9%) 188 (2.0%) < 0.001 73 (1.2%) 75 (1.3%) 0.869
Left anterior descending 6535 (52.3%) 3988 (42.4%) < 0.001 2885 (49.0%) 2869 (48.7%) 0.768
Left circumflex 1138 (9.1%) 2603 (27.7%) < 0.001 932 (15.8%) 932 (15.8%) 1.000
Right coronary artery 4705 (37.7%) 2621 (27.9%) < 0.001 2001 (34.0%) 2015 (34.2%) 0.786
Treated vessel:
Left main 196 (1.6%) 332 (3.5%) < 0.001 133 (2.3%) 129 (2.2%) 0.803
Left anterior descending 7414 (59.4%) 5202 (55.3%) < 0.001 3436 (58.3%) 3444 (58.5%) 0.881
Left circumflex 2027 (16.2%) 3733 (39.7%) < 0.001 1535 (26.1%) 1504 (25.5%) 0.514
Right coronary artery 5301 (42.4%) 3486 (37.1%) < 0.001 2415 (41.0%) 2414 (41.0%) 0.985
Æ
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between the groups were compared using the log-
rank test. For all analyses, a two-sided p < 0.05 was 
considered statistically significant. All statistical 
analyses were performed using SPSS software, 
version 20 (IBM; Armonk, NY, USA) [7].
Results
Baseline clinical, laboratory, angiographic, 
and procedural characteristics
In the total study population, the mean age 
of the NSTEMI group was greater than that of 
the STEMI group (64.2 ± 12.0 years vs. 61.9 ± 
12.6 years, p < 0.001, Table 1). The following val-
ues were higher in the STEMI group than in the 
NSTEMI group: number of men; value of cardio-
genic shock, cardiopulmonary resuscitation (CPR), 
and current smokers; levels of CK-MB, troponin I, 
blood glucose, total cholesterol, high-density 
lipoprotein (HDL)-cholesterol, and low-density 
lipoprotein (LDL)-cholesterol; prescription rates of 
clopidogrel and cilostazol; numbers of PCI within 
24 hours, left anterior descending artery (LAD, 
infract-related artery [IRA] and treated vessel) and 
right coronary artery (RCA, IRA and treated ves-
sel); and numbers of American College of Cardiol-
ogy/American Heart Association (ACC/AHA) type 
C and 1-vessel disease. By contrast, the NSTEMI 
Table 1 (cont.). Baseline clinical, laboratory, angiographic, and procedural characteristics.











Left main 196 (1.6%) 332 (3.5%) < 0.001 133 (2.3%) 129 (2.2%) 0.803
Left anterior descending 7414 (59.4%) 5202 (55.3%) < 0.001 3436 (58.3%) 3444 (58.5%) 0.881
Left circumflex 2027 (16.2%) 3733 (39.7%) < 0.001 1535 (26.1%) 1504 (25.5%) 0.514
Right coronary artery 5301 (42.4%) 3486 (37.1%) < 0.001 2415 (41.0%) 2414 (41.0%) 0.985
ACC/AHA lesion type:
Type B1 1745 (14.0%) 1448 (15.4%)  0.003 875 (14.9%) 908 (15.4%) 0.396
Type B2 3706 (29.7%) 3418 (36.4%) < 0.001 1969 (33.4%) 1984 (33.7%) 0.770
Type C 5911 (47.3%) 3752 (39.9%) < 0.001 2543 (43.2%) 2488 (42.2%) 0.306
Extent of coronary artery disease:
1-vessel 6534 (52.3%) 4040 (43.2%) < 0.001 2809 (47.7%) 2774 (47.1%) 0.518
2-vessel 3701 (29.6%) 3212 (34.2%) < 0.001 1882 (31.9%) 1895 (32.2%) 0.797
≥ 3-vessel 2255 (18.1%) 2148 (22.9%) < 0.001 1200 (20.4%) 1222 (20.7%) 0.616
Multi-vessel disease 5956 (47.7%) 5360 (57.0%) < 0.001 3082 (52.3%) 3117 (52.9%) 0.518
Drug-eluting stents:
BMS 834 (6.7%) 534 (5.7%)  0.003 344 (5.8%) 358 (6.1%) 0.586
SES 1941 (15.5%) 1207 (12.8%) < 0.001 782 (13.3%) 815 (13.8%) 0.374
PES 1667 (13.3%) 1123 (11.9%)  0.002 747 (12.7%) 716 (12.2%) 0.386
ZES 2780 (22.3%) 2006 (21.3%) 0.104 1254 (21.3%) 1273 (21.6%) 0.670
EES 3548 (28.4%) 3168 (33.7%) < 0.001 1939 (32.9%) 1885 (32.0%) 0.288
BES 1012 (8.1%) 1002 (10.7%) < 0.001 543 (9.2%) 541 (9.2%) 0.949
Stent diameter [mm] 3.20 ± 0.42 3.10 ± 0.42 < 0.001 3.14 ± 0.41 3.14 ± 0.42 0.572
Stent length [mm] 26.1 ± 9.1 26.7 ± 11.2 < 0.001 26.5 ± 9.9 26.5 ± 10.4 0.965
Number of stents 1.41 ± 0.72 1.60 ± 0.88 < 0.001 1.51 ± 0.80 1.52 ± 0.79 0.811
Values are mean ± standard deviation or number (%). The p values for continuous data were obtained from analysis of the unpaired t-test. 
The p values for categorical data were obtained from chi-square test. STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-
-STEMI; LVEF — left ventricular ejection fraction; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; 
CPR — cardiopulmonary resuscitation; PCI — percutaneous coronary intervention; MI — myocardial infarction; CABG — coronary artery  
bypass graft; CVA — cerebrovascular accident; HF — heart failure; CK-MB — creatine kinase myocardial band; NT-proBNP — N-terminal  
pro-B-type natriuretic peptide; hs-CRP — high-sensitivity-C-reactive protein; HDL — high-density lipoprotein; LDL — low-density lipoprotein; 
ASA — acetylsalicylic acid; CCB — calcium channel blockers; ACC/AHA — American College of Cardiology/American Heart Association; 
BMS — bare-metal stent; SES — sirolimus-eluting stent; PES — paclitaxel-eluting stent; ZES — zotarolimus-eluting stent; EES — everolimus-
-eluting stent; BES — biolimus-eluting stent
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group showed higher values than the STEMI 
group for the following: left ventricular ejection 
fraction (LVEF, 54.6 ± 11.1% vs. 51.5 ± 10.8%, 
p < 0.001); systolic blood pressure; diastolic blood 
pressure; number of patients with hypertension, 
diabetes, dyslipidemia, previous history of MI, PCI, 
coronary artery bypass graft, heart failure (HF), 
and cerebrovascular accident; levels of serum 
N-terminal pro-B-type natriuretic peptide and se-
rum creatinine; prescription rates of ticagrelor and 
calcium channel blockers; the number of left main 
coronary artery (LM, IRA and treated vessel), left 
circumflex artery (LCx, IRA and treated vessel); 
and the frequency of multi-vessel disease (MVD). 
Bare-metal stents (BMS) and first-generation 
DESs were more frequently deployed in the STEMI 
group, and the everolimus-eluting stents and 
biolimus-eluting stents were more frequently de-
Table 2. Clinical outcomes by Kaplan-Meier analysis and Cox-proportional hazard ratio analysis up to  
2 years.
Outcomes Cumulative events at 2-year (%)
STEMI NSTEMI Log-rank Hazard ratio (95% CI) P
Total study population
MACEs 851 (7.2) 728 (8.3) 0.003 1.159 (1.050–1.280) 0.003
All-cause death 228 (1.9) 255 (2.9) < 0.001 1.512 (1.265–1.808) < 0.001
Cardiac death 164 (1.4) 170 (1.9) 0.002 1.398 (1.128–1.733) 0.002
Re-MI 181 (1.5) 149 (1.7) 0.319 1.117 (0.899–1.387) 0.319
Total repeat revascularization: 507 (4.3) 399 (4.7) 0.310 1.070 (0.939–1.220) 0.310
TLR 160 (1.4) 122 (1.4) 0.774 1.035 (0.818–1.310) 0.774
TVR 294 (2.5) 244 (2.8) 0.153 1.132 (0.955–1.341) 0.154
Non-TVR 222 (1.9) 162 (1.9) 0.933 0.991 (0.810–1.214) 0.933
Propensity score-matched patients
MACEs 414 (7.4) 452 (8.2) 0.132 1.108 (0.969–1.266) 0.132
All-cause death 114 (2.0) 158 (2.9) 0.005 1.407 (1.106–1.790) 0.005
Cardiac death 82 (1.4) 106 (1.9) 0.046 1.311 (0.983–1.749) 0.046
Re-MI 94 (1.7) 90 (1.7) 0.847 0.972 (0.728–1.298) 0.847
Total repeat revascularization: 241 (4.4) 252 (4.7) 0.485 1.065 (0.893–1.271) 0.485
TLR 85 (1.5) 71 (1.3) 0.308 0.849 (0.619–1.163) 0.308
TVR 150 (2.7) 150 (2.8) 0.871 1.019 (0.813–1.278) 0.871
Non-TVR 98 (1.8) 107 (2.0) 0.444 1.113 (0.846–1.464) 0.444
Multivariate analysis*
MACEs 851 (7.2) 728 (8.3) 0.003 1.081 (0.965–1.210) 0.178
All-cause death 228 (1.9) 255 (2.9) < 0.001 1.528 (1.264–1.852) 0.001
Cardiac death 164 (1.4) 170 (1.9) 0.002 1.406 (1.146–1.802) 0.020
Re-MI 181 (1.5) 149 (1.7) 0.319 1.021 (0.798–1.308) 0.866
Total repeat revascularization: 507 (4.3) 399 (4.7) 0.310 0.975 (0.839–1.134) 0.746
TLR 160 (1.4) 122 (1.4) 0.774 0.857 (0.653–1.124) 0.264
TVR 294 (2.5) 244 (2.8) 0.153 0.979 (0.805–1.190) 0.830
Non-TVR 222 (1.9) 162 (1.9) 0.933 0.963 (0.764–1.213) 0.748
*Adjusted by age, men, LVEF, SBP, DBP, cardiogenic shock, CPR on admission, hypertension, diabetes, dyslipidemia, previous history of MI, 
PCI, CABG, HF, and CVA, current smoker, serum level of CK-MB, troponin I, NT-proBNP, blood glucose, CCB, PCI within 24 hours, IRA, treated 
vessel, ACC/AHA type B2, and C lesion, the extent of coronary artery disease, types of stents (SES, EES, and BES), stent diameter, stent 
length, and number of stents. STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-STEMI; CI — confidence interval;  
MACE — major adverse cardiac events; Re-MI — re-myocardial infarction; TLR — target lesion revascularization: TVR — target vessel revas-
cularization; Non-TVR — non-TVR; LVEF — left ventricular ejection fraction; SBP — systolic blood pressure; DBP — diastolic blood pressure; 
CPR — cardiopulmonary resuscitation; MI — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery  
bypass graft; HF — heart failure; CVA — cerebrovascular accidents; CK-MB — creatine kinase myocardial band; NT-proBNP — N-terminal 
pro-B-type natriuretic peptide; CCB — calcium channel blockers; IRA — infarct-related artery; ACC/AHA — American College of Cardiology/ 
/American Heart Association; SES — sirolimus-eluting stent; EES — everolimus-eluting stents; BES — biolimus-eluting stents
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ployed in the NSTEMI group. After PSM analysis, 
baseline differences between the two groups were 
well balanced. However, the blood levels of CK-MB 
and troponin I levels were not well balanced. 
Clinical outcomes
In the total study population, the cumula-
tive incidence of MACEs (hazard ratio [HR] 
1.159; 95% confidence interval [CI] 1.050–1.280; 
p = 0.003, Fig. 2A), all-cause death (HR 1.512; 
95% CI 1.265–1.808; p < 0.001), and CD (HR 
1.398; 95% CI 1.128–1.733; p = 0.002) were higher 
in the NSTEMI group than in the STEMI group. 
After PSM analysis, the cumulative incidence of 
MACEs was not significantly different between 
the groups (Fig. 2B). However, the cumulative 
incidences of all-cause death (HR 1.407; 95% CI 
1.106–1.790; p = 0.005, Fig. 2C) and CD (HR 
1.311; 95% CI 0.983–1.749; p = 0.046, Fig. 2D) 
were significantly higher in the NSTEMI group 
Figure 2. Kaplan-Meier analysis for major adverse cardiac events (MACEs) (A, B), all-cause death (C), and cardiac 
death (D); PSM — propensity score-matched; HR — hazard ratio; CI — confidence interval; NSTEMI — non-ST-
-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction.
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than in the STEMI group. Before and after PSM 
analysis, the cumulative incidences of Re-MI, any 
repeat revascularization, TLR, TVR, and non-TVR 
were not statistically different between the groups. 
Figure 3 shows subgroup analysis for MACEs at 
2 years. In cases of male sex (HR 1.13; 95% CI 
1.00–1.27; p = 0.047), low LVEF (< 50%, HR 
1.47; 95% CI 1.26–1.71; p < 0.001), cardiogenic 
shock (HR 1.17; 95% CI 1.06–1.29; p = 0.002), and 
PCI within 24 hours (HR 1.15; 95% CI 1.03–1.28; 
p = 0.012) statins combined with RASI showed 
greater reduction in MACEs for patients with 
STEMI than for those with NSTEMI. Advanced 
age (≥ 65 years), low LVEF (< 50%), diabetes, 
CPR on admission, N-terminal pro-B-type natriu-
retic peptide, serum creatinine, total cholesterol, 
triglyceride, LDL-cholesterol, PCI within 24 hours, 
BMS, and MVD were meaningful independent risk 
factors for both all-cause death and CD in PSM 
patients (Table 3).
Discussion
According to current guidelines [5, 6, 8, 9], 
more than 80% of the patients with AMI received 
statin therapy in Korea [16]. Similarly, more than 
50% of these patients received RASI therapy 
to reduce cardiovascular mortality [17]. How-
ever, the comparative studies regarding long-term 
clinical outcomes of statin with RASI combination 
therapy between STEMI and NSTEMI after stent 
implantation have not been reported. We believe 
this may be the first report focusing on this issue. 
Moreover, the present study confirms that statin 
combined with RASI was more effective in patients 
with STEMI rather than in patients with NSTEMI 
with respect to all-cause death and CD rates over 
a 2-year follow-up.
The key findings of this study are as follows: 
First, after PSM analysis, the cumulative inci-
dences of all-cause death and CD were significantly 
higher in patients with NSTEMI than in those with 
STEMI after combined statin and RASI therapy. 
Second, the cumulative incidences of MACEs, 
Re-MI, and any repeat revascularization including 
TLR, TVR, and non-TVR were not significantly dif-
ferent between the two groups after PSM analysis. 
Third, advanced age (≥ 65 years), male sex, low 
LVEF (< 50%), diabetes, CPR on admission, PCI 
within 24 hours, BMS, and MVD were independ-
ent risk factors for both all-cause death and CD in 
PSM patients. 
Statins both reduce LDL-cholesterol and 
decrease the occurrences of cardiovascular death, 
non-fatal MI, and repeat coronary revasculariza-
tion by inhibiting 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase activity, as 
well as other not fully understood processes [3, 
18, 19]. The beneficial effects of statins are evident 
in both STEMI and NSTEMI patients [5, 6, 8, 9]. 
However, data comparing the long-term prognosis 
of STEMI and NSTEMI patients, especially those 
focused on the usage of statins, are limited. In 
the era of DES, Kim et al. [7] demonstrated that 
MACEs and mortality reduction capacity of statin 
therapy was prominent compared with statin non-
use, and statins were more effective in patients 
with STEMI compared with NSTEMI. Regardless 
of STEMI or NSTEMI, RASI provides mortality 
reduction benefit by diminishing the rate of pro-
gressive LV dilation and remodeling, especially in 
patients with LV dysfunction [5, 6]. Even though 
Kim et al. [10] reported greater reduction in mor-
tality following RASI in STEMI patients than in 
NSTEMI patients after successful PCI, long-term 
clinical outcome data comparing the status of 
STEMI and NSTEMI patients post successful 
stent implantation after combined statin and RASI 
therapy are also limited. Koh et al. [20] suggested 
that combined statins and RASI may improve en-
dothelial function, insulin resistance, and athero-
sclerosis. In our study, the cumulative incidences 
of all-cause death (HR 1.407; 95% CI 1.106–1.790; 
p = 0.005) and CD (HR 1.311; 95% CI 0.983–1.749; 
p = 0.046) were also significantly higher in the 
NSTEMI group than in the STEMI group. Taken 
together, these results suggest that RASI mono-
therapy or statins combined with RASI was more 
beneficial for STEMI patients than for NSTEMI 
patients in terms of reduced mortality. Statins 
decrease the production of oxygen-derived free 
radicals by reducing LDL-cholesterol, increasing 
nitric oxide (NO) synthesis, promoting antioxidant 
effects, and inhibiting upregulation of angiotensin 
II type 1 (AT1) receptor expression. RASI inhibits 
binding of angiotensin II to the AT1 receptor and 
induces decreased production of oxygen-derived 
free radicals. Accumulated bradykinins after ACEI 
treatment lead to increased stimulation of NO 
production [20]. NO production may be a shared 
process for both statins and RASI. Kim et al. [10] 
showed that RASI after PSM was more effective 
in reducing all-cause death (HR 1.386; 95% CI 
1.114–1.725; p = 0.003) and CD (HR 1.358; 95% CI 
1.041–1.7770; p = 0.024) in patients with STEMI 
compared with NSTEMI after PSM. However, we 
found that statins combined with RASI did not 
show greater relative risk reduction of all-cause 
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Table 3. Multivariate Cox-proportional regression analysis for predictors of all-cause death and cardiac 
death in propensity score-matched patients.
Variables All-cause death Cardiac death
HR (95% CI) P HR (95% CI) P
STEMI vs. NSTEMI 2.822 (2.102–3.789) < 0.001 2.643 (1.858–3.759) < 0.001
Age ≥ 65 years 2.617 (1.945–3.521) < 0.001 2.491 (1.748–3.551) < 0.001
Male 1.009 (0.774–1.315) 0.949 1.057 (0.770–1.450) 0.733
LVEF < 50% 1.961 (1.531–2.510) < 0.001 1.887 (1.403–2.540) < 0.001
Systolic blood pressure 0.991 (0.982–0.999) 0.024 0.992 (0.983–1.002) 0.121
Diastolic blood pressure 1.012 (0.999–1.026) 0.072 1.010 (0.994–1.027) 0.204
Hypertension 1.186 (0.916–1.535) 0.196 1.236 (0.905–1.689) 0.183
Diabetes mellitus 1.522 (1.184–1.956) 0.001 1.453 (1.074–1.967) 0.015
Dyslipidemia 1.140 (0.758–1.715) 0.528 1.086 (0.693–1.702) 0.720
Cardiogenic shock 1.074 (0.517–2.233) 0.847 1.372 (0.524–3.591) 0.519
CPR on admission 3.289 (2.034–5.318) < 0.001 4.001 (2.322–6.895) < 0.001
CK-MB 1.000 (0.999–1.001) 0.814 1.000 (0.999–1.001) 0.969
Troponin-I 1.000 (1.000–1.001) 0.407 1.000 (1.000–1.001) 0.497
NT-proBNP 1.001 (1.000–1.002) < 0.001 1.002 (1.001–1.003) < 0.001
hs-CRP 1.001 (0.999–1.003) 0.256 1.000 (0.998–1.003) 0.766
Serum creatinine 1.128 (1.074–1.186) < 0.001 1.124 (1.057–1.195) < 0.001
Total cholesterol 0.994 (0.991–0.997) < 0.001 0.992 (0.989–0.996) < 0.001
Triglyceride 0.996 (0.994–0.998) < 0.001 0.996 (0.994–0.999) 0.001
HDL-cholesterol 0.993 (0.982–1.003) 0.173 0.994 (0.981–1.006) 0.308
LDL-cholesterol 0.994 (0.991–0.998) 0.001 0.993 (0.989–0.997) 0.001
Beta-blocker 1.562 (1.038–2.353) 0.033 1.600 (0.978–2.617) 0.061
PCI within 24 hours 1.483 (1.167–1.885) 0.001 1.395 (1.046–1.860) 0.024
LAD (IRA) 1.122 (0.752–1.676) 0.572 1.020 (0.633–1.643) 0.934
LAD (treated) 1.120 (0.744–1.686) 0.586 1.065 (0.659–1.721) 0.796
ACC/AHA type B2/C lesion 1.124 (0.824–1.533) 0.461 1.007 (0.703–1.442) 0.970
BMS 3.104 (1.905–5.056) < 0.001 2.481 (1.360–4.527) 0.003
SES 1.940 (1.048–3.591) 0.035 2.041 (0.974–4.275) 0.059
PES 1.343 (0.755–2.389) 0.316 1.142 (0.591–2.210) 0.692
ZES 1.128 (0.702–1.813) 0.618 1.084 (0.616–1.909) 0.780
EES 1.150 (0.725–1.824) 0.552 1.112 (0.642–1.924) 0.706
BES 1.066 (0.606–1.874) 0.825 1.196 (0.598–2.390) 0.613
MVD 1.301 (1.003–1.687) 0.048 1.343 (0.981–1.840) 0.042
Stent diameter 0.856 (0.630–1.162) 0.317 0.714 (0.490–1.040) 0.079
Stent length 0.999 (0.987–1.012) 0.883 0.998 (0.983–1.013) 0.791
HR — hazard ratio; CI — confidence interval; STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-STEMI; LVEF — left  
ventricular ejection fraction; CPR — cardiopulmonary resuscitation; CK-MB — creatine kinase myocardial band; NT-proBNP — N-terminal  
pro-B-type natriuretic peptide; hs-CRP — high sensitivity-C-reactive protein; HDL — high-density lipoprotein; LDL — low-density lipoprotein;  
PCI — percutaneous coronary intervention; LAD — left anterior descending coronary artery; IRA — infarct-related artery; ACC/AHA — American 
College of Cardiology/American Heart Association; BMS — bare-metal stent; SES — sirolimus-eluting stent; PES — paclitaxel-eluting stent; 
ZES — zotarolimus-eluting stent; EES — everolimus-eluting stent; BES — biolimus-eluting stent; MVD — multivessel disease
death (40.7% vs. 38.6%) or CD (31.1% vs. 35.8%) 
compared with the results of Kim et al. [10]. We 
speculated that one of the major causative factors 
for the similar relative risk reduction potency for 
all-cause death and CD in these two studies (Kim 
et al. [10] and the present study) is related, at 
least in part, with this shared NO production pro-
cess [19]. This has included suggestion that this 
similar NO mediated protective mechanism may 
be attenuated their effects on endothelium each 
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other. However, this supposition supports the 
need for further study to confirm these findings. 
Other possible factor for these results was the 
presence of BMS. BMS was not included in the 
Kim et al. [10] study. However, the proportion of 
BMS in the total study population was low, and 
BMS was an independent significant predictor for 
both all-cause death and cardiac death in PSM pa-
tients (Table 3). Nevertheless, with regard to the 
beneficial effect of statin monotherapy by reducing 
MACEs, all-cause death, and TVR in patients with 
STEMI [7], statin and RASI combination therapy 
showed an additional beneficial effect on reducing 
the cumulative incidence of CD (HR 1.311; 95% 
CI 0.983–1.749; p = 0.046) in this study.
On PSM analysis, many patients (10,108/ 
/21,890, 46.2%) were excluded and the serum 
CK-MB and troponin-I levels were not well-
matched. To overcome these limitations, we 
performed standard multivariate analysis. Never-
theless, the results of multivariate analysis were 
similar to the results of the PSM analysis. After 
multivariate analysis, the cumulative incidences 
of all-cause death (HR 1.528; 95% CI 1.264–1.852; 
p = 0.001) and CD (HR 1.406; 95% CI 1.146–
–1.802; p = 0.020) were significantly higher in 
NSTEMI patients than in STEMI patients. The 
cumulative incidences of MACEs, Re-MI, and any 
repeat revascularization were similar between 
the two groups (Table 2). 
The condition of the STEMI group was worse 
than that of the NSTEMI group with respect to 
baseline characteristics. The values of cardiogenic 
shock (5.2% vs. 1.6%, p < 0.001) and CPR on ad-
mission (2.9% vs. 1.4%, p < 0.001); the number 
of current smokers (48.6% vs. 38.5%, p < 0.001), 
LAD (IRA, treated vessel), RCA (IRA, treated 
vessel), and ACC/AHA type C; and the levels of 
CK-MB, troponin I were significantly higher in the 
STEMI group. However, the cumulative incidences 
of all-cause death and CD were significantly lower 
in the STEMI group than in the NSTEMI group. 
These results were associated with the beneficial 
effects of RASI and were compatible with those 
of the OPTIMAAL study [21]. In the OPTIMAAL 
study, the clinical benefit of RASI was larger in 
the high-risk patient subgroup, including anterior 
MI, decreased LVEF (≤ 40%), HF, prior MI, and 
tachycardia. On subgroup analysis, for patients who 
had decreased LVEF and who were in cardiogenic 
shock, statin combined with RASI reduced MACEs 
in patients with STEMI more than in those with 
NSTEMI (Fig. 3). 
Another considerable factor for determining 
the cumulative incidences of all-cause death and 
CD was the treatment strategy. In the present 
study, 93.5% (11,627/12,490) of the STEMI 
patients had undergone primary PCI, and about 
79.2% (7444/9400) of the NSTEMI patients had 
received early invasive treatment. The higher 
incidence of primary PCI may be associated with 
favorable all-cause death rates and CD in STEMI 
patients. Currently, the reasons for the higher 
incidence of death in NSTEMI during long-term 
follow-up remain poorly understood [22, 23]. In 
patients with NSTEMI, studies recommended 
that a selective invasive strategy may be prefer-
able in selected patients to improve long-term 
outcomes [24, 25].
KAMIR is a nationwide, prospective, observa-
tional, on-line registry in South Korea that has been 
compiling data since November 2005. More than 50 
high-volume university and community hospitals 
with facilities for primary PCI and onsite cardiac sur-
gery have participated [13]. Therefore, we believe 
the population of this study is sufficiently large to 
provide reasonably accurate results. Furthermore, 
the results of this comparative study may persuade 
interventional cardiologists of the benefits of statins 
combined with RASI with respect to reducing all-
cause death and CD in STEMI patients compared 
with those in NSTEMI patients after PCI.
Limitations of the study
Our study had several limitations. First, there 
may be some under-reporting and/or missed data 
because of the non-randomized retrospective 
nature of the study. Second, our study was based 
on medications at discharge, and the registry data 
did not include full detailed data concerning the 
starting time of statin or RASI therapy, changes 
in prescription doses, long-term adherence, or dis-
continuation during the follow-up period; therefore, 
these factors may contribute bias. Third, we could 
not provide serial follow-up results compared with 
initial laboratory results because of limitations 
related to the registry data; this too may introduce 
bias. Fourth, we reported 2-year clinical outcomes 
between the two groups in this study; neverthe-
less, a 2-year follow-up period is relatively short 
for the determination of long-term major clinical 
outcomes. Finally, the long inclusion period could 
also have influenced the patient’s profile and may 
have biased the results, because RASI, AT1, and 
statins in recent years have been modernized in 
late generations with, generally, better bioprofile. 
10 www.cardiologyjournal.org
Cardiology Journal 20XX, Vol. XX, No. X
Conclusions
In conclusion, despite the fact that the cumula-
tive incidences of MACEs, Re-MI, and any repeat 
revascularization including TLR, TVR, and non-TVR 
were not statistically significantly different between 
the two groups, with respect to all-cause death and 
CD rates during a 2-year follow-up period, combined 
use of statin with RASI was more effective in patients 
with STEMI than in those with NSTEMI. However, 
further studies are warranted to elucidate this focus.
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